NHS, Vertex Strike Deal to Make Kaftrio Available in England

NHS England and Vertex Pharmaceuticals have reached an agreement that will allow access to Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), a triple combination therapy for cystic fibrosis (CF) to be used in a combination regimen with Kalydeco, as soon as the medication is approved by the European…

Vertex, NHS England Reach Agreement on Pricing and Public Availability of CF Treatments

Vertex Pharmaceuticals has reached an agreement with England’s National Health Service (NHS), allowing patients there access to all Vertex cystic fibrosis (CF) treatments currently approved in Europe at low or no out-of-pocket cost. The agreement between the NHS and Vertex appears to end a long-standing dispute over the company’s pricing…

Vertex Offers England a Portfolio Approach for Access to Orkambi and Future CF Therapies

Vertex Pharmaceuticals is offering the England arm of Britain’s National Health Service a package deal on the pricing of its current and future cystic fibrosis therapies. What the company describes as “a bold new portfolio approach” to pricing comes in the wake of the National Health Service balking at covering…